Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Guselkumab for Giant Cell Arteritis
Recruiting0 awardsPhase 2
Los Angeles, California
This trial is testing guselkumab, a medication that blocks a protein causing inflammation, in adults with new or returning giant cell arteritis. The goal is to see if it helps reduce symptoms. Guselkumab has been approved for treatment of multiple immunologic diseases including psoriasis and palmoplantar pustulosis.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service